Association of Single‐Nucleotide Polymorphism 3 and c.553G>T ofAPOA5with Hypertriglyceridemia after Treatment with Highly Active Antiretroviral Therapy Containing Protease Inhibitors in HIV‐Infected Individuals in Taiwan

We investigated the relationship between hypertriglyceridemia and the single-nucleotide polymorphisms (SNPs) on APOA5 in human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) in Taiwan. Receipt of protease inhibitor-based HAART, high baseline triglyceride levels, and carriage of APOA5 SNP3 or c.553G>T variants or APOA5 SNP1T/SNP2G/SNP3C/c.553T haplotype were statistically significantly associated with development of extreme hypertriglyceridemia (triglyceride level, >500 mg/dL).